Should You Be Worried About Gilead Sciences, Inc.'s (NASDAQ:GILD) 5.7% Return On Equity?
Insider Sale: Johanna Mercier Sells 29,357 Shares of Gilead Sciences Inc (GILD)
Gilead Sciences Insider Sold Shares Worth $2,459,577, According to a Recent SEC Filing
Mizuho Securities Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $90
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
Daily short sale tracking: Warner Bros Discovery's short volume increased by 4 million, with a short sale ratio of 16%
Marengo Therapeutics Enters Clinical Study Collaboration And Supply Agreement With Gilead Sciences
Express News | Marengo Therapeutics: Under Agreement, Gilead Will Provide Trodelvy to Marengo
Marengo Therapeutics Announces Clinical Study Collaboration With Gilead Sciences to Evaluate Invikafusp Alfa (STAR0602) and Trodelvy in Both Metastatic TNBC and Metastatic HR+/HER2- Breast Cancers
J.P. Morgan Maintains Gilead Sciences(GILD.US) With Buy Rating
Buy Rating Affirmed for Gilead Sciences on Lenacapavir's Market-Changing Potential in PrEP
BMO Capital Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $85
US stocks closed: Technology breaks through to lift the index, Nasdaq and S&P jointly achieve four consecutive gains.
① After four consecutive days of gains, the S&P 500 index is still 1.3% away from its historical high. ② Warren Buffett's deputy sold more than half of Berkshire Hathaway's positions, causing the stock price to fall for the seventh consecutive day. ③ AirPods Pro transforms into an OTC hearing aid, with FDA approval for Apple's hearing assistance software. ④ Gilead's HIV prevention drug delivers positive results once again.
Why Gilead Sciences Stock Thrashed the Market Today
Gilead Sciences Options Spot-On: On September 12th, 191.56K Contracts Were Traded, With 260.56K Open Interest
Gilead Sciences Goes Ex-dividend Tomorrow
Gilead Sciences' (NASDAQ:GILD) Latest Study Shows Further Effectiveness Against HIV
What the Options Market Tells Us About Gilead Sciences
Gilead's HIV-prevention Drug Cut Infections by 96%, Boosting Stock
Helping End HIV - Gilead Sciences